N -substituted-piperidines as Novel Anti-alzheimer Agents: Synthesis, antioxidant activity, and molecular docking study

[1]  M. Pudlo,et al.  Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease. , 2014, Bioorganic & medicinal chemistry.

[2]  A. Shafiee,et al.  Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. , 2013, European journal of medicinal chemistry.

[3]  P. Nordlund,et al.  Fragment-based ligand design of novel potent inhibitors of tankyrases. , 2013, Journal of medicinal chemistry.

[4]  P. Agostinho,et al.  Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-induced neurotoxicity. , 2013, ACS chemical neuroscience.

[5]  D. Dougherty.  The cation-π interaction. , 2013, Accounts of chemical research.

[6]  José Marco-Contelles,et al.  Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease , 2013, Medicinal research reviews.

[7]  M. Rudolph,et al.  Structures of human acetylcholinesterase in complex with pharmacologically important ligands. , 2012, Journal of medicinal chemistry.

[8]  M. Decker,et al.  Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo. , 2012, Journal of medicinal chemistry.

[9]  V. Andrisano,et al.  Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. , 2011, European journal of medicinal chemistry.

[10]  M. Al-Omar,et al.  Synthesis, antiplatelet aggregation activity, and molecular modeling study of novel substituted-piperazine analogues , 2011, Medicinal Chemistry Research.

[11]  H. Jacobsen,et al.  Alzheimer's disease: from pathology to therapeutic approaches. , 2009, Angewandte Chemie.

[12]  L. Wessjohann,et al.  (Iso)-quinoline alkaloids from fungal fruiting bodies of Cortinarius subtortus. , 2008, Journal of natural products.

[13]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[14]  G. Perry,et al.  Prevention and treatment of Alzheimer disease and aging: antioxidants. , 2007, Mini reviews in medicinal chemistry.

[15]  S. Moore,et al.  The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design. , 2006, Current pharmaceutical design.

[16]  Hiroaki Kazui,et al.  Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? , 2005, The American journal of psychiatry.

[17]  Charles L. Brooks,et al.  Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..

[18]  Ian D. Williams,et al.  Dimerization of an Inactive Fragment of Huperzine A Produces a Drug with Twice the Potency of the Natural Product , 2000 .

[19]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[20]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[21]  R B D'Agostino,et al.  Lifetime risk of dementia and Alzheimer's disease , 1997, Neurology.

[22]  J. Sussman,et al.  Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. , 1993, Chemico-biological interactions.

[23]  A. Gader,et al.  A Study of the Normal Pattern of Platelet Aggregation in Healthy Saudis: A Population-based Study. , 1990, Platelets.

[24]  A. Gader,et al.  Dose-Response Aggregometry in Maternal/Neonatal Platelets , 1988, Thrombosis and Haemostasis.